Patterson's iWatch wanna-be is certainly not directly

New Post Public Reply Private Reply Replies (1) Message Board
havasu78 havasu78 #78832
801
Patterson's iWatch wanna-be is certainly not directly related to Cytodyn, but it may be closer than Cytodyn adjacent.

Patterson's concept is that every patient is an investigator.

Covid is multifactorial and every patient's experience is relevant to discovering the best treatment path.

Patterson's complaint is that the notion of precision medicine is completely lost on the vast majority of physicians.

So much so that when he reviewed patient files from very sick covid patients during Christmas break, Patterson learned that "hospital physicians were unaware of the immune status of their severe/critical patients".

Hard to know exactly what Patterson means, but I suspect he is saying something to the effect that the hospital physicians do not lab test severe/critical patients to figure out whether the patients are in the viral phase or the cytokine phase of covid disease.

I read Patteson's complaint to mean that most physicians are Luddites.

I read Patterson's complaint to mean that most physicians, even highly trained hospital specialists treating severe/critical covid patients, cannot adapt to new concepts which they cannot understand.

I read Patterson's compalints to mean that most physicians do not understand what Patterson is doing.

One brief snippet of Paterson's comments included the tidbit that the types of tests which Patterson runs are traditionally viewed as "research" and not used for clinical practice.

Maybe its true that cytokine and chemokine test panels are not normally employed in clinical practice.

Maybe its true that RNA, DNA, and single cell genomics are not typically used in clinical practice.

Certainly its true that no one but Patterson, at least at the moment, is employing his long hauler index, which is an algebra formula on several lab test results.

Possibly Patterson is the first, and still only, medical person to feed a big data matrix into an AI correlator program with the expectation that the AI would spit out the dispositive medical parameters, idk.

So perhaps Patterson is breaking some new ground in diagnostic medicine.

Perhaps the paradigm shift will include analysis of multifactorial data sets in diseases that have multifactorial causes.

Perhaps, especially in chronic diseases, several data vectors will be collected from wearable 24hr patient monitors.

Patterson/Yo will collect multifactorial data for the multifactorial disease, covid19.

Patterson/Yo will employ a wearable 24hr patient monitor to collect some of this data.

Patterson/Yo will aggregate thousands of individual patient datasets.

Seems to me this approach might also work for other multifactorial diseases.

According to Patterson, CCR5 is the "quarterback" of the immune system.

Cytodyn's many experiments in cancer, liver disease, CNS, and covid suggest Patterson may have badly underestimated the importance of CCR5 in many multifactorial diseases.

So suppose Patterson makes some progress with his newfangled immune profiling tool and that it proves useful for covid long haulers.

That means that immune system surveillance is a critical tool in the treatment of the multifactorial immune disease covid19.

Well, cancer is an immune disease for certain. MS is an immune disease for certain. Alzheimer's has an inflammatory component for certain. (Arguably every disease is an immune disease because every disease can be defeated by a powerfully functioning immune system.)

So seems to me that if successful in covid19, the Patterson tools will be applied to many other diseases.

And if immune surveillance is critical for covid19, and the next step is to apply immune surveillance to other chronic diseases, what tools for immune surveillance will be used?

Maybe all the cancer, MS, NASH, and who knows what else will follow if a successful example in immune surveillance for covid19.

If it catches on fast, Patterson's tools might be the only tools available.

Seems to me that Cytodyn cancer trial patients could be wearing Patterson watches in the near future.

Gaylis may already be on board the Patterson/Yo train. How long will it take for others to hop on board?

Well, Cdiddy, probably a far too long and circuitous answer to your very simple question. I guess i just have too much free time on my hands

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 24

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 19

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 19

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 14

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 21

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 24

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Decoding FS KKR's Legal Woes and Stock Woes Tonight

Updated Category News Views 29

FS KKR's Legal Quagmire Unpacked On the surface, investing in stocks might seem like a no-brainer. But when giants like FS KKR Capital Corp. (NYSE:FSK) find themselves tangled in legal webs, it's time to delve deeper and question everything we've taken as gospel. Recently, the collective anxiety in boardrooms is reflected in a class action lawsuit against FS KKR, filed by...

Continue Reading
Yukon Metals Unveils Ambitious Exploration Strategy for Birch

Updated Category News Views 148

Yukon Metals Unveils Expansion Plans for Birch Property Yukon Metals Corp. has announced its dynamic plans for the Birch Property, pushing to enhance resource identification in the mineral-rich region. This initiative focuses on a 7,000-hectare area, positioned strategically to capitalize on copper and gold resources. With collaborative efforts from local contractors,...

Continue Reading
Nuclearn Sets New Standards with Innovative AI for Nuclear Sectors

Updated Category News Views 378

Nuclearn Revolutionizes Nuclear Industry with AI Innovations In the realm of nuclear energy, efficiency and accuracy are paramount. Nuclearn has taken a bold step forward by introducing its groundbreaking Agentic AI solutions. This innovative approach is not only a technological leap but also a paradigm shift for professionals working in nuclear environments. An...

Continue Reading
Lithium Americas Secures $2.26 Billion in DOE Loan Boosting Stock

Updated Category News Views 162

Exciting Developments for Lithium Americas Corp. Lithium Americas Corp. (NYSE: LAC) is experiencing a notable surge in its stock price as it recently secured a substantial $2.26 billion loan from the U.S. Department of Energy’s (DOE) Loan Programs Office. This funding falls under the Advanced Technology Vehicles Manufacturing Loan Program, marking a significant...

Continue Reading
Quarterly Earnings Preview: North American Insights

Updated Category News Views 209

Quarterly Earnings Preview of North American North American (NYSE: NOA) is set to unveil its quarterly earnings report soon. This announcement is eagerly awaited by investors, with analysts predicting an earnings per share (EPS) of $0.86. Investors are hopeful that the earnings will not only meet these expectations but exceed them, along with offering positive guidance...

Continue Reading